IP Library Granted Patent US 10,107,809
Granted Patent B2
US 10,107,809 · App. 15/078,038 · Granted Oct 23, 2018

Glass bead flow rates to facilitate immunodiagnostic test element manufacture

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,107,809
App. No.
15/078,038
Granted
Oct 23, 2018
Kind
B2
Abstract

A method is provided for of preparing a glass bead mixture using inert nanoparticles to improve flow rates of the glass beads for purposes of manufacturing an immunodiagnostic test element, such as a column agglutination test cassette. The immunodiagnostic test element includes a plurality of test columns including an aqueous reagent in each test column.

Claims (34)

1. A method for manufacturing and using an immunodiagnostic test element having a plurality of test columns provided on a planar substrate, each of the test columns having an open upper end, the method comprising the steps of:

washing a plurality of glass beads;

placing the plurality of washed glass beads in a mixing apparatus;

placing a quantity of inert nanoparticles in the mixing apparatus, in which the glass beads and the nanoparticles include the same material;

mixing together the plurality of glass beads and the inert nanoparticles using the mixing apparatus, such that the inert nanoparticles adhere to the exterior of said beads;

flowing the mixed glass beads and inert nanoparticles from the mixing apparatus into at least one test column of the immunodiagnostic test element;

adding an aqueous reagent to the at least one test column, the aqueous reagent causing the inert nanoparticles to dissociate from the glass beads; and

conducting a test using the immunodiagnostic test element by adding a sample to the at least one test column, and centrifuging the immunodiagnostic test element to create an agglutination reaction wherein formed agglutinates are caused to flow from an upper portion of the at least one test column through the glass beads toward the bottom of the at least one test column.

2. The method according to claim 1 , wherein the plurality of glass beads each comprise at least about 85% SiO 2 .

3. The method according to claim 2 , wherein the plurality of glass beads comprise borosilicate glass beads comprising a size of between about 50-120 μm diameter.

4. The method according to claim 3 , wherein the plurality of glass beads comprise borosilicate glass beads comprising a size of between about 65-90 μm diameter.

5. The method according to claim 4 , wherein the plurality of glass beads comprise borosilicate glass beads comprising a size of between about 75-90 μm diameter.

6. The method according to claim 1 , wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing an amount of nanoparticles equivalent to about 0.0001% to about 1.0% by weight as between the inert nanoparticles and the glass beads.

7. The method according to claim 6 , wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing an amount of nanoparticles equivalent to about 0.0005% to about 0.1% by weight as between the inert nanoparticles and the glass beads.

8. The method according to claim 7 , wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing an amount of nanoparticles equivalent to about 0.0005% to about 0.0015% by weight as between the inert nanoparticles and the glass beads.

9. The method according to claim 1 , wherein the step of placing inert nanoparticles in the mixing apparatus comprises placing nanoparticles having an agglomerate size equivalent to about 1 μm.

10. The method according to claim 9 , wherein the inert nanoparticles comprise at least about 99% or more SiO 2 .

11. The method according to claim 9 , wherein the step of mixing together the plurality of glass beads and the inert nanoparticles includes reducing the size of the inert nanoparticles to between about 0.1 to 0.2 μm in aggregate, each aggregate comprised of a plurality of primary particles.

12. The method according to claim 1 , wherein the step of washing comprises using an acid wash, or a combination of a caustic wash and an acid wash.

13. A method for improving flowability of glass beads in an immunodiagnostic test element, said test element including a plurality of test columns, the immunodiagnostic test element being used to perform agglutination reactions of an applied sample using column agglutination technology, said method comprising:

washing a plurality of the glass beads;

placing the plurality of glass beads in a mixing apparatus;

placing a preselected quantity of inert nanoparticles in the mixing apparatus in which the glass beads and the nanoparticles include the same material;

mixing together the plurality of glass beads and the inert nanoparticles using the mixing apparatus, wherein the inert nanoparticles are caused to adhere to the exterior surface of said glass beads;

flowing the mixture of the glass beads and the inert nanoparticles from the mixing apparatus into the test columns of the immunodiagnostic test element; and

placing an aqueous reagent into the test columns in which the aqueous reagent causes the inert nanoparticles to dissociate from the glass beads.

14. The method according to claim 13 , further comprising securing the plurality of test columns in parallel in a rigid package.

15. The method according to claim 13 , wherein the step of placing a preselected quantity of inert nanoparticles in the mixing apparatus comprises placing fumed silica in the mixing apparatus at about 0.0001% to about 1.0% by weight as between the fumed silica and the glass beads.

16. The method according to claim 15 , wherein the step of placing a preselected quantity of inert nanoparticles in the mixing apparatus comprises placing fumed silica in the mixing apparatus at about 0.0005% to about 0.1% by weight as between the fumed silica and the glass beads.

17. The method according to claim 16 , wherein the step of placing a preselected quantity of inert nanoparticles in the mixing apparatus comprises placing fumed silica in the mixing apparatus at about 0.0005% to about 0.0015% by weight as between the fumed silica and the glass beads.

18. The method according to claim 13 , wherein the plurality of glass beads comprise borosilicate glass beads having a diameter of between about 50-120 μm.

19. The method according to claim 18 , wherein the plurality of glass beads comprise borosilicate glass beads having a diameter of between about 65-90 μm.

20. The method according to claim 19 , wherein the plurality of glass beads comprise borosilicate glass beads having a diameter of between about 75-90 μm.

21. The method according to claim 15 , wherein the inert nanoparticles adhered to the exterior surface of said glass beads comprise fumed silica particles fused into aggregates having a size of about 0.1 μm to about 0.2 μm.

Assignments (5)
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC
Reel/Frame 060219/0571 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
SECURITY AGREEMENT Recorded Nov 6, 2018
From: ORTHO-CLINICAL DIAGNOSTICS, INC.
To: BARCLAYS BANK PLC
Reel/Frame 047435/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2016
From: CROWTHER, JONATHAN BURR; SUROWITZ, AMY LOUISE; LUCZAK, ANNA KRYSTYNA
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 038077/0784 →